Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IGC Pharma, Inc. filings document a clinical-stage biotechnology issuer with common stock listed on NYSE American under the symbol IGC. The company's regulatory disclosures cover material-event reports, operating and financial results, clinical and regulatory updates tied to Alzheimer's disease programs, and capital-structure matters including promissory note financing and authorized share changes.
Form 8-K disclosures also record amendments to governing documents, the fiscal year-end change to December 31, shareholder voting results, board election and auditor ratification matters, and equity incentive share approvals. These filings frame the company's governance, financing arrangements, reporting calendar and development-stage disclosure profile.
IGC Pharma, Inc. reports results for the quarter ended March 31, 2026, as it advances its Alzheimer’s pipeline and AI platforms. Revenue was $317 thousand, slightly below $330 thousand a year earlier, and still comes mainly from life sciences wellness and white‑label products rather than drug sales. The company posted a net loss of $2.4 million, double the $1.2 million loss in the prior-year quarter, driven by higher R&D spending on the Phase 2 CALMA trial of IGC-AD1 and increased stock-based compensation. Cash and cash equivalents fell to $207 thousand, with a working capital deficit of $1.7 million, partly mitigated by $710 thousand of new equity and debt financing, a $12 million credit facility, and cost actions including the sale of a loss-making facility. Management expects continued operating losses while focusing on completing the CALMA trial, developing the MINT-AD AI platform, and progressing additional Alzheimer’s candidates.
IGC Pharma entered into two securities purchase agreements, issuing promissory notes to FirstFire Global Opportunities Fund and Vanquish Funding Group to raise cash for general working capital. The FirstFire note has a principal of $346,910 (including original issue discount) and matures on April 10, 2027, while the VFG note has a principal of $238,050 and matures on March 30, 2027.
Both notes carry a 12% interest rate and may be prepaid in full with notice. If an Event of Default occurs and continues, each holder may convert amounts outstanding into common stock at a price equal to 75% of the lowest trading price over the prior ten trading days, subject to a 4.99% beneficial ownership limit and an overall 19.99% Conversion Cap unless shareholders approve more under NYSE American rules.
IGC Pharma director Richard K. Prins exercised restricted stock units into common shares of the company. On April 1, 2026, he converted 170,000 restricted stock units into 170,000 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he directly holds 1,541,251 shares of IGC Pharma common stock. The units were granted in June 2023 and March 2024 and vest in equal installments over three years, with each unit representing one share of common stock.
IGC Pharma, Inc. CEO Mukunda Ram reported multiple equity award exercises on April 1, 2026. He exercised restricted stock units and stock options to acquire a total of 706,409 shares of common stock, including shares held indirectly through his spouse, with no open-market sales.
Following these transactions, Ram directly holds 4,649,088 shares of IGC Pharma common stock, while his spouse holds an additional 910,751 shares reported as indirect ownership. The filing reflects routine compensation-related vesting and option exercises rather than discretionary buying or selling.
IGC Pharma director James P. Moran reported routine equity compensation activity involving restricted stock units (RSUs). On April 1, 2026, he exercised 80,000 RSUs and 50,000 RSUs, each RSU converting into one share of IGC common stock at a $0.00 exercise price. These RSUs stem from grants made on June 20, 2023 and March 13, 2024 that vest in equal annual installments over three years. Following the conversions, Moran directly owns 1,235,735 shares of IGC Pharma common stock, with no open‑market sales disclosed in this filing.
IGC Pharma director and PFO Claudia Grimaldi exercised equity awards to acquire additional common stock. On April 1, 2026, she converted 100,000 Restricted Stock Units into 100,000 shares of common stock and exercised options for 138,462 shares at an exercise price of $0.26 per share.
These exercises increased her direct holdings to 1,372,714 shares of common stock. The RSUs and options were originally granted in June 2023 and March 2024, respectively, and vest in equal installments over three years.
IGC Pharma, Inc. entered into a strategic 12-part national media partnership with FMW Media Works’ New to The Street platform to support its investor relations and corporate communications. The campaign will use long-form TV interviews, commercials, digital channels, and outdoor placements in major U.S. financial markets.
IGC will appear on sponsored programming on Fox Business and Bloomberg Television, with additional reach through more than 4.45 million YouTube subscribers, Times Square and New York City Financial District billboards, and curated events aimed at accredited investors. The company frames this effort as enhancing investor awareness while it advances its clinical-stage Alzheimer’s and metabolic disorder pipeline.
IGC Pharma, Inc. filed a Transition Report on Form 10-KT for the nine-month fiscal transition period ended December 31, 2025 following a Board-approved change of fiscal year end from March 31 to December 31. The company remains a clinical-stage biotech focused on Alzheimer’s disease; its lead candidate, IGC-AD1, is in a Phase 2 CALMA trial for agitation in Alzheimer’s dementia with approximately two-thirds of target enrollment completed and interim signals reported from an initial n=26 cohort showing reductions in agitation and exploratory sleep improvements. Nonclinical work during the period included a genetic toxicology study that did not identify genotoxic risk. Financially, cash and cash equivalents were approximately $900,000 and the company reported a working capital deficit of approximately $366,000 as of December 31, 2025. Shares outstanding were 98,796,089 as of March 11, 2026.
IGC Pharma, Inc. entered into new financing arrangements, including a promissory note with Vanquish Funding Group Inc. for a total principal of $353,050, reflecting an original issue discount of $46,050 on a cash purchase price of $307,000. The note matures on February 28, 2027 and can be prepaid at any time with notice. If an event of default occurs and continues, Vanquish may convert the outstanding balance into common shares at 75% of the lowest trading price over the prior 10 trading days, subject to a 4.99% beneficial ownership cap and a 19.99% conversion cap absent shareholder approval. IGC also obtained approximately $219,000 in additional financing through a loan agreement with One Deck Capital, Inc. Both financings are intended for general working capital and other corporate purposes.
IGC Pharma's CEO and director Ram Mukunda reported indirect transactions involving his spouse's holdings. On February 3, 2026, his spouse acquired 50,000 shares of common stock at $0.0 per share, bringing indirectly held common stock to 860,752 shares.
On the same date, the spouse was granted 16,667 restricted stock units that vest immediately and 66,666 restricted stock units that vest over time, both indirectly attributed "BY SPOUSE." Each restricted stock unit represents the right to receive one share of IGC common stock.